FrancophonIA/ELRC3.0 huggingface dataset:
English: Most toxicity was consistent with pharmacology related to urinary glucose loss and included decreased body weight and body fat, increased food consumption, diarrhoea, dehydration, decreased serum glucose and increases in other serum parameters reflective of increased protein metabolism, gluconeogenesis and electrolyte imbalances, and urinary changes such as polyuria, glucosuria, and calciuria.
Danish: Størstedelen af toksiciteten svarede til farmakologien relateret til glucosetab i urinen og omfattede reduceret legemsvægt og kropsfedt, øget fødeindtagelse, diarré, dehydrering, nedsat serumglucose og stigninger i andre serumparametre, der afspejler øget proteinmetabolisering, gluconeogenese og forstyrrelser i elektrolytbalancen samt urinændringer som f.eks. polyuri, glukosuri og kalkariuri.
English: Steglatro should not be used in patients with severe renal impairment, with end-stage renal disease (ESRD), or receiving dialysis, as it is not expected to be effective in these patients.
Danish: Steglatro må ikke anvendes hos patienter med svært nedsat nyrefunktion, terminal nyresygdom (ESRD) eller patienter i dialyse, da det ikke forventes at virke hos disse patienter.
English: Dysuria, Blood creatinine increased/Glomerular filtration rate decreased
Danish: Dysuri, forhøjet indhold af kreatinin i blodet/nedsat glomerulær filtrationsrate
English: Consideration may also be given to stopping treatment with ertugliflozin in patients who develop events which may precede amputation such as lower-extremity skin ulcer, infection, osteomyelitis or gangrene.
Danish: Det kan også overvejes at afbryde behandlingen med ertugliflozin hos patienter, der udvikler lidelser, der kan være forløbere for amputation, som f.eks. sår på underekstremitet, infektion, osteomyelitis eller gangræn.
English: Steglatro is available in Alu/PVC/PA/Alu blisters.
Danish: Steglatro fås i Alu/PVC/PA/Alu-blistre.
English: In three 26-week, placebo-controlled studies, ertugliflozin reduced systolic blood pressure (SBP).
Danish: I tre 26-ugers placebokontrollerede studier reducerede ertugliflozin det systoliske blodtryk.
English: “702” on one side and plain on the other side.
Danish: “702” på den ene side og uden prægning på den anden side.
English: “701” on one side and plain on the other side.
Danish: “701” på den ene side og uden prægning på den anden side.
English: It is not known if Steglatro passes into breast milk.
Danish: Det er ukendt, om Steglatro går over i modermælken.
English: The safety and efficacy of ertugliflozin in children under 18 years of age have not been established.
Danish: Pædiatrisk population Ertugliflozins sikkerhed og virkning hos børn under 18 år er ikke klarlagt.
English: Ertugliflozin has been studied as monotherapy and in combination with metformin and/or a dipeptidyl peptidase 4 (DPP-4) inhibitor.
Danish: Ertugliflozin er blevet undersøgt som monoterapi og i kombination med metformin og/eller en DPP-4 (dipeptidylpeptidase)-hæmmer.
English: Before initiating ertugliflozin, consider factors in the patient history that may increase the risk for amputation.
Danish: Før behandling med ertugliflozin initieres, skal faktorer i patientens anamnese, som kan forøge risikoen for amputation, tages i betragtning.
English: • The starting dose of Steglatro is one 5-mg tablet each day.
Danish: • Startdosis for Steglatro er en 5 mg-tablet hver dag.
English: Coadministration of simvastatin with ertugliflozin resulted in a 24% and 19% increase in AUC and Cmax of simvastatin, respectively, and 30% and 16% increase in AUC and Cmax of simvastatin acid, respectively.
Danish: Samtidig administration af simvastatin og ertugliflozin medførte en stigning på henholdsvis 24% og 19% i AUC og Cmax for simvastatin og en stigning på henholdsvis 30% og 16% i AUC og Cmax for simvastatinsyre.
English: 14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 30x1 film-coated tablets 84 film-coated tablets 90 film-coated tablets 98 film-coated tablets
Danish: 14 filmovertrukne tabletter 28 filmovertrukne tabletter 30 filmovertrukne tabletter 30x1 filmovertrukne tabletter 84 filmovertrukne tabletter 90 filmovertrukne tabletter 98 filmovertrukne tabletter
English: Taking this medicine in combination with insulin or medicines that increase insulin release from the pancreas can cause blood sugar levels to drop too low (hypoglycaemia), which may cause symptoms such as shaking, sweating and change in vision, and may affect your ability to drive and use machines.
Danish: Brug af dette lægemiddel i kombination med insulin eller lægemidler, der øger insulinfrigivelsen fra bugspytkirtlen, kan medføre, at blodsukkerniveauet bliver for lavt (hypoglykæmi), hvilket kan forårsage symptomer som rysten, svedtendens og ændret syn, og kan påvirke evnen til at føre motorkøretøj og betjene maskiner.
English: In the pool of placebo-controlled studies, the incidence of adverse events related to volume depletion (dehydration, dizziness postural, presyncope, syncope, hypotension, and orthostatic hypotension) was low (< 2%) and not notably different across the ertugliflozin and placebo groups.
Danish: I den poolede analyse af placebokontrollerede studier var incidensen af bivirkninger relateret til volumendepletering (dehydrering, postural svimmelhed, præsynkope, synkope, hypotension og ortostatisk hypotension) lav (<2%) og ikke markant forskellig på tværs af ertugliflozin- og placebogrupperne.
English: Increased urination‡
Danish: Øget vandladning‡
English: SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation.
Danish: SGLT2 er det dominerende transportprotein, der er ansvarlig for reabsorption af glucose fra det glomerulære filtrat tilbage i kredsløbet.
English: The efficacy and safety of ertugliflozin have been studied in 7 multi-centre, randomised, double-blind, placebo- or active comparator-controlled, Phase 3 clinical studies involving 4,863 patients with type 2 diabetes, including a study of 468 patients with moderate renal impairment.
Danish: Ertugliflozins virkning og sikkerhed er blevet undersøgt i 7 randomiserede, dobbeltblindede, placeboog aktivt komparator-kontrollerede kliniske multicenter-studier i fase 3 med 4.863 patienter med type 2-diabetes, herunder et studie med 468 patienter med moderat nedsat nyrefunktion.
English: Do not use Steglatro if you are pregnant.
Danish: Tag ikke Steglatro, hvis du er gravid.
English: The risk of diabetic ketoacidosis must be considered in the event of non-specific symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness.
Danish: Risikoen for diabetisk ketoacidose skal overvejes ved ikke-specifikke symptomer som f.eks. kvalme, opkastning, anoreksi, abdominalsmerter, udtalt tørst, vejrtrækningsbesvær, forvirring, usædvanlig træthed eller søvnighed.
English: The major metabolic pathway for ertugliflozin is UGT1A9 and UGT2B7-mediated O-glucuronidation to two glucuronides that are pharmacologically inactive at clinically relevant concentrations.
Danish: Den primære metaboliseringsvej for ertugliflozin er UGT1A9 og UGT2B7-medieret O-glucuronidering til to glucuronider, der er farmakologisk inaktive ved klinisk relevante koncentrationer.
English: Ertugliflozin works by blocking the SGLT2 protein in your kidneys.
Danish: Ertugliflozin virker ved at blokere SGLT2-proteinerne i nyrerne.
English: In patients tolerating ertugliflozin 5 mg once daily, the dose can be increased to 15 mg once daily if additional glycaemic control is needed.
Danish: Hos patienter, som tåler ertugliflozin 5 mg en gang dagligt, kan dosis øges til 15 mg en gang dagligt, hvis der er behov for yderligere glykæmisk kontrol.
English: Blood creatinine increased/Glomerular filtration rate decreased and renal-related events Initial increases in mean creatinine and decreases in mean eGFR in patients treated with ertugliflozin were generally transient during continuous treatment.
Danish: Forhøjet kreatinin i blodet/nedsat glomerulær filtrationsrate og nyrerelaterede hændelser Initiale gennemsnitlige stigninger i kreatinin og nedsat gennemsnitlig eGFR hos patienter, der fik ertugliflozin, var generelt forbigående under kontinuerlig behandling.
English: Interference with 1,5-anhydroglucitol (1,5-AG) assay Monitoring glycaemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycaemic control in patients taking SGLT2 inhibitors.
Danish: Interferens med 1,5 anhydroglucitol (1,5 AG)-analyse Monitorering af glykæmisk kontrol med 1,5 AG-analysen frarådes, da målinger af 1,5 AG er upålidelige til vurdering af glykæmisk kontrol hos patienter, der tager SGLT2-hæmmere.
English: Based on results from animal studies, ertugliflozin may affect renal development and maturation (see section 5.3).
Danish: Baseret på resultater fra dyreforsøg kan ertugliflozin påvirke udviklingen og modningen af nyrerne (se pkt.
English: Before initiating ertugliflozin, factors in the patient history that may predispose to ketoacidosis should be considered.
Danish: Inden initiering af behandlingen med ertugliflozin skal der tages højde for faktorer i patientens anamnese, der kan prædisponere for ketoacidose.
English: Following administration of an oral C]-ertugliflozin solution to healthy subjects, approximately 41% and 50% of the drug-related radioactivity was eliminated in faeces and urine, respectively.
Danish: C]-ertugliflozin-opløsning til raske forsøgspersoner blev ca. 41% og 50% af den lægemiddelrelaterede radioaktivitet elimineret i henholdsvis fæces og urin.
English: Patients who may be at higher risk of DKA include patients with a low beta-cell function reserve (e.g., type 2 diabetes patients with low C-peptide or latent autoimmune diabetes in adults (LADA) or patients with a history of pancreatitis), patients with conditions that lead to restricted food intake or severe dehydration, patients for whom insulin doses are reduced and patients with increased insulin requirements due to acute medical illness, surgery, or alcohol abuse.
Danish: Patienter, der kan have en højere risiko for diabetisk ketoacidose, omfatter patienter med lav restfunktion af betaceller (f.eks. patienter med type 2-diabetes med lavt C-peptid eller latent autoimmun diabetes hos voksne eller patienter med pankreatitis i anamnesen), patienter med tilstande, der medfører lav fødeindtagelse eller svær dehydrering, patienter, hvis insulindosis er blevet nedsat, og patienter med øget insulinbehov på grund af akut sygdom, kirurgi eller alkoholmisbrug.
English: Restarting SGLT2 inhibitor treatment in patients with previous DKA while on SGLT2 inhibitor treatment is not recommended, unless another clear precipitating factor is identified and resolved.
Danish: Det anbefales ikke at genoptage behandlingen med SGLT2-hæmmer hos patienter, der tidligere har haft diabetisk ketoacidose under behandling med SGLT2-hæmmer, medmindre en anden tydelig medvirkende faktor identificeres og afhjælpes.
English: Packs of 14, 28, 30, 84, 90 and 98 film-coated tablets in non-perforated blisters.
Danish: Pakninger med 14, 28, 30, 84, 90 og 98 filmovertrukne tabletter i ikke-perforerede blistre.
English: In patients with volume depletion, correcting this condition prior to initiation of ertugliflozin is recommended (see section 4.4).
Danish: Hos patienter med volumendepletering anbefales det at afhjælpe denne tilstand inden initiering af behandling med ertugliflozin (se pkt.
English: Monitoring of renal function is recommended as follows: - Prior to ertugliflozin initiation and periodically during treatment (see section 4.2).
Danish: Monitorering af nyrefunktionen anbefales som følger: - Inden initiering af behandling med ertugliflozin og periodisk under behandlingen (se pkt.
English: Ertugliflozin has also been studied in combination with current diabetes treatments, including insulin and a sulphonylurea, in patients with type 2 diabetes with moderate renal impairment.
Danish: Ertugliflozin er også blevet undersøgt i kombination med aktuelle diabetesbehandlinger, herunder insulin og et sulfonylurinstof, hos patienter med type 2-diabetes med moderat nedsat nyrefunktion.
English: • experience rapid weight loss, feeling sick or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat contact a doctor or the nearest hospital straight away.
Danish: • oplever hurtigt vægttab, kvalme eller opkastning, mavesmerter, ekstrem tørst, hurtig og dyb vejrtrækning, forvirring, usædvanlig søvnighed eller træthed, sødlig ånde, sødlig eller metallisk smag i munden, eller at din urin eller sved lugter anderledes.
English: In the event of an overdose, employ the usual supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment) as dictated by the patient's clinical status.
Danish: Ved overdosering skal de sædvanlige understøttende foranstaltninger iværksættes (f.eks. fjernelse af ikke-optaget materiale fra mave-tarm-kanalen, anvendelse af klinisk monitorering og igangsætning af understøttende behandling) afhængig af patientens kliniske status.
English: Steglatro contains lactose (milk sugar).
Danish: Steglatro indeholder lactose (mælkesukker).
English: Non-inferiority is declared when the upper bound of the two-sided 95% confidence interval (CI) for the mean difference is less than 0.3%.
Danish: Non-inferioritet erklæres, når den øvre grænse af det tosidede 95%-konfidensinterval (CI) for middelforskellen er under p< 0,001 sammenlignet med glimepirid.
English: Steglatro should not be used to treat this condition.
Danish: Steglatro må ikke anvendes til at behandle denne sygdom.
English: • Swallow the tablet; if you have difficulties with swallowing, the tablet can be broken or crushed.
Danish: • Synk tabletten; tabletten kan deles eller knuses, hvis du har synkebesvær.
English: Pharmacotherapeutic group: Drugs used in diabetes, Sodium glucose co-transporter 2 (SGLT2) inhibitors, ATC code: A10BK04.
Danish: Farmakoterapeutisk klassifikation: Antidiabetika, natrium-glucose-co-transporter 2 (SGLT2)hæmmere, ATC-kode: A10BK04.
English: • in addition to other medicinal products for the treatment of diabetes.
Danish: • som supplement til andre antidiabetika.
English: Effects on bone (shorter femur length, increased trabecular bone in the femur) as well as effects of delayed puberty were observed at an exposure 817 times the MRHD of 15 mg/day based on AUC.
Danish: Indvirkning på knoglerne (kortere lårbenslængde, længere trabekulær lårbensknogle) samt indvirkning i form af forsinket pubertet blev observeret ved en eksponering på 817 gange MRHD på 15 mg/dag baseret på AUC.
English: Across the clinical program, ketoacidosis was identified in 3 of 3,409 (0.1%) ertugliflozin-treated patients and 0.0% of comparator-treated patients (see section 4.4).
Danish: I det kliniske program blev der identificeret ketoacidose hos 3 ud af 3.409 (0,1%) ertugliflozinbehandlede patienter og 0,0% hos patienterne i komparatorgruppen (se pkt.
English: Your doctor will decide whether to increase your dose to 15 mg.
Danish: Lægen beslutter, om din dosis skal øges til
English: Pool of placebo-controlled trials evaluating Steglatro 5 mg and 15 mg The primary assessment of safety was conducted in a pool of three 26-week, placebo-controlled trials.
Danish: Poolede placebokontrollerede studier til vurdering af Steglatro 5 mg og 15 mg Den primære sikkerhedsvurdering blev udført som en poolet analyse af tre 26-ugers, placebokontrollerede studier.
English: p< 0.001 compared to control group.
Danish: p< 0,001 sammenlignet med kontrolgruppe.
English: What you need to know before you take Steglatro 3.
Danish: Det skal du vide, før du begynder at tage Steglatro 3.
English: The tablets contain lactose monohydrate.
Danish: Tabletterne indeholder lactosemonohydrat.
English: (For study results with respect to combinations and effects on glycaemic control see sections 4.4, 4.5, and 5.1.)
Danish: (For studieresultater vedrørende kombinationer og effekt på glykæmisk kontrol, se pkt.
English: Following single-dose oral administration of 5 mg and 15 mg of ertugliflozin, peak plasma concentrations (median Tmax) of ertugliflozin occur at 1 hour postdose under fasted conditions.
Danish: Efter oral administration af enkeltdosis på 5 mg og 15 mg ertugliflozin opnås maksimale plasmakoncentrationer (median Tmax) af ertugliflozin 1 time efter dosering under fastende forhold.
English: Interaction studies conducted in healthy subjects, using a single dose design, suggest that the pharmacokinetics of ertugliflozin are not altered by sitagliptin, metformin, glimepiride, or simvastatin.
Danish: Interaktionsstudier udført med raske forsøgspersoner i enkeltdosisdesign tyder på, at ertugliflozins farmakokinetik ikke ændres af sitagliptin, metformin, glimepirid eller simvastatin.
English: Change from baseline (LS mean Difference from placebo (LS mean
Danish: Baseline (gennemsnit) Ændring fra baseline Forskel fra placebo
English: Ertugliflozin has no or negligible influence on the ability to drive and use machines.
Danish: Ertugliflozin påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner.
English: Hypromellose 2910/6 (E464) Lactose monohydrate Macrogol 3350 (E1521) Triacetin (E1518) Titanium dioxide (E171) Iron oxide red (E172)
Danish: Hypromellose 2910/6 (E464) Lactosemonohydrat Macrogol 3350 (E1521) Triacetin (E1518) Titandioxid (E171) Rød jernoxid (E172)
English: In an ongoing clinical study of ertugliflozin added to existing therapy in type 2 diabetes patients with a history of established cardiovascular disease, an approximately 1.2-1.6-fold increase in cases of lower limb amputation (primarily of the toe) has been observed in patients treated with ertugliflozin.
Danish: I et igangværende klinisk studie med ertugliflozin som tillæg til eksisterende behandling hos patienter med type 2-diabetes med fastsat kardiovaskulær sygdom i anamnesen er der observeret en stigning på cirka 1,2-1,6 gange i antallet af amputationer af underekstremiteter (primært en tå) hos patienter, der fik ertugliflozin.
English: Pink, 6.4 x 6.6 mm, triangular-shaped, film-coated tablets debossed with “701” on one side and plain on the other side.
Danish: Lyserøde, 6,4 x 6,6 mm, trekantede, filmovertrukne tabletter præget med “701” på den ene side og uden prægning på den anden side.
English: In a subsequent analysis excluding those subjects who used the prohibited medication, ertugliflozin 5 mg and 15 mg were associated with placebo-corrected reductions in HbA1c of -0.14 (-0.36, 0.08) and -0.33 (-0.55, -0.11)
Danish: I en efterfølgende analyse, som ekskluderede de forsøgspersoner, som havde anvendt forbudt medicin, blev ertugliflozin 5 mg og ertugliflozin 15 mg associeret med placebokorrigerede fald i HbA1c på -0,14 (-0,36; 0,08) og -0,33
English: Red, 9.0 x 9.4 mm, triangular-shaped, film-coated tablets debossed with “702” on one side and plain on the other side.
Danish: Røde, 9,0 x 9,4 mm, trekantede, filmovertrukne tabletter præget med “702” på den ene side og uden prægning på den anden side.
English: EU/1/18/1267/007 (14 film-coated tablets) EU/1/18/1267/008 (28 film-coated tablets) EU/1/18/1267/009 (30 film-coated tablets) EU/1/18/1267/010 (30x1 film-coated tablets) EU/1/18/1267/011 (84 film-coated tablets) EU/1/18/1267/012 (90 film-coated tablets) EU/1/18/1267/014 (98 film-coated tablets)
Danish: EU/1/18/1267/007 (14 filmovertrukne tabletter) EU/1/18/1267/008 (28 filmovertrukne tabletter) EU/1/18/1267/009 (30 filmovertrukne tabletter) EU/1/18/1267/010 (30x1 filmovertrukne tabletter) EU/1/18/1267/011 (84 filmovertrukne tabletter) EU/1/18/1267/012 (90 filmovertrukne tabletter) EU/1/18/1267/014 (98 filmovertrukne tabletter)
English: Effects of ertugliflozin on the pharmacokinetics of other medicinal products Interaction studies conducted in healthy volunteers suggest that ertugliflozin had no clinically relevant effect on the pharmacokinetics of sitagliptin, metformin, and glimepiride.
Danish: Ertugliflozins indvirkning på andre lægemidlers farmakokinetik Interaktionsstudier udført med raske frivillige forsøgspersoner tyder på, at ertugliflozin ikke havde en klinisk relevant indvirkning på farmakokinetikken for sitagliptin, metformin og glimepirid.
English: When ertugliflozin was administered to juvenile rats from postnatal day (PND) 21 to PND 90, a period of renal development corresponding to the late second and third trimesters of human pregnancy, increased kidney weights, dilatation of the renal pelvis and tubules, and renal tubular mineralization were seen at an exposure 13 times the maximum clinical dose of 15 mg/day, based on AUC.
Danish: Når ertugliflozin blev administreret til unge rotter fra postnatal dag (PND) 21 til PND 90, blev der observeret en periode med nyreudvikling svarende til slutningen af det andet og det tredje trimester af en human graviditet, øget nyrevægt, dilatation af nyrebækkenet og de renale tubuli samt mineralisering af de renale tubuli ved en eksponering på 13 gange den maksimale kliniske dosis på 15 mg/dag, baseret på AUC.
English: The placebo-corrected reductions of ertugliflozin 5 or 15 mg in combination with sitagliptin were 2.16 and 2.56 mmol/l.
Danish: De placebokorrigerede fald i ertugliflozin 5 eller 15 mg i kombination med sitagliptin var på 2,16 og 2,56 mmol/l.
English: EU/1/18/1267/001 (14 film-coated tablets) EU/1/18/1267/002 (28 film-coated tablets) EU/1/18/1267/003 (30 film-coated tablets) EU/1/18/1267/004 (30x1 film-coated tablets) EU/1/18/1267/005 (84 film-coated tablets) EU/1/18/1267/006 (90 film-coated tablets) EU/1/18/1267/013 (98 film-coated tablets)
Danish: EU/1/18/1267/001 (14 filmovertrukne tabletter) EU/1/18/1267/002 (28 filmovertrukne tabletter) EU/1/18/1267/003 (30 filmovertrukne tabletter) EU/1/18/1267/004 (30x1 filmovertrukne tabletter) EU/1/18/1267/005 (84 filmovertrukne tabletter) EU/1/18/1267/006 (90 filmovertrukne tabletter) EU/1/18/1267/013 (98 filmovertrukne tabletter)
English: Steglatro 15 mg film-coated tablets EU/1/18/1267/007
Danish: Steglatro 15 mg filmovertrukne tabletter EU/1/18/1267/007
English: If you get any side effects, talk to your doctor or, pharmacist or nurse.
Danish: Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken.
English: The LS mean (95% CI) changes from baseline in HbA1c were -0.26 (-0.42, -0.11), -0.29 (-0.44, -0.14), and -0.41 (-0.56, -0.27) in the placebo, ertugliflozin 5 mg, and ertugliflozin 15 mg groups, respectively.
Danish: Ændringerne fra HbA1c-baseline (mindste kvadraters gennemsnit (95% CI)) var henholdsvis -0,26 (-0,42; -0,11), -0,29 (-0,44; -0,14) og -0,41 (-0,56; -0,27) i placebogruppen, ertugliflozin 5 mggruppen og ertugliflozin 15 mg-gruppen.
English: Difference from placebo (LS mean
Danish: Forskel fra placebo
English: Steglatro 5 mg film-coated tablets EU/1/18/1267/001
Danish: Steglatro 5 mg filmovertrukne tabletter EU/1/18/1267/001
English: • Steglatro 15 mg film-coated tablets (tablets) are red, 9.0 x 9.4 mm, triangular-shaped, with
Danish: • Steglatro 15 mg filmovertrukne tabletter (tabletter) er røde, 9,0 x 9,4 mm, trekantede, med
English: Steglatro is a member of a group of medicines called sodium glucose co-transporter-2 (SGLT2) inhibitors.
Danish: Steglatro tilhører en lægemiddelklasse kaldet SGLT2-hæmmere (natrium-glucose-co-transporter 2).
English: Least squares means adjusted based on a longitudinal model including terms for treatment, time, and the interaction of time by treatment.
Danish: Mindste kvadraters gennemsnit justeret på baggrund af en longitudinal model, herunder termer for behandling, tid og interaktion mellem tid og behandling.
English: The pack sizes are 14, 28, 30, 84, 90 and 98 filmcoated tablets in non-perforated blisters and 30x1 film-coated tablets in perforated unit dose blisters.
Danish: Pakningsstørrelserne er 14, 28, 30, 84, 90 og 98 filmovertrukne tabletter i ikke-perforerede blistre og 30 x 1 filmovertrukne tabletter i perforerede enkeltdosisblistre.